Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer-Reference-Cited by-同舟云学术

Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer

Published:2018-10-15 Issue:4 Volume:50 Page:1418-1432
ISSN:1598-2998
Container-title:Cancer Research and Treatment
language:en
Short-container-title:Cancer Res Treat

Author:

Ahn Soomin,Kim Hyun Jeong,Kim Milim,Chung Yul Ri,Kang Eunyoung,Kim Eun-Kyu,Kim Se Hyun,Kim Yu Jung,Kim Jee Hyun,Kim In Ah,Park So Yeon

Funder

National Research Foundation of Korea

Ministry of Science, ICT and Future Planning

Publisher

Korean Cancer Association

Subject

Cancer Research,Oncology

Link

http://e-crt.org/upload/pdf/crt-2017-552.pdf

Reference30 articles.

1. Neoadjuvant treatment of breast cancer

2. St Gallen International Expert Consensus on the primary therapy of early breast cancer: an invaluable tool for physicians and scientists

3. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer

5. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Applicability of Quantum Dots in Breast Cancer Diagnostic and Therapeutic Modalities—A State-of-the-Art Review;Nanomaterials;2024-08-31

2. NGS mutational status on first diagnostic tissue, liquid biopsy and mastectomy in G2–G3 breast cancer;Romanian Journal of Morphology and Embryology;2024-07-15

3. HER2-low breast cancer and response to neoadjuvant chemotherapy: a population-based cohort study;Pathology;2024-04

4. Changing the phenotype of breast cancer in the process treatment: literature review;Surgery and Oncology;2024-01-04

5. Récepteur du facteur de croissance épidermique HER2, tests utilisés pour rechercher son amplification dans le cancer du sein : principes et limites;Bulletin du Cancer;2023-12